Kidney function may affect hepatitis b drug levels

NCT ID NCT07168356

Ongoing Knowledge-focused Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study gives a single dose of bepirovirsen to 32 adults with hepatitis B, some with kidney disease and some healthy. Researchers measure how much drug gets into the blood and how long it stays. The goal is to see if kidney problems change drug levels, which could affect future dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bepirovirsen
What this could lead to: If successful, this study could help doctors determine the right dose of bepirovirsen for hepatitis B patients with kidney problems.
What could go wrong: This is a very early, small study (32 people) focused on drug levels, not on treating hepatitis B. It may not lead to any treatment changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease hepatitis B virus infection kidney disorder kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B

Contacts and locations

Locations

GSK Investigational Site

Orlando, Florida, 32809, United States
GSK Investigational Site

Tampa, Florida, 33603, United States
GSK Investigational Site

San Antonio, Texas, 78215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.